Amplyx: The inside track

Amplyx Pharmaceuticals Inc. believes its cell sequestration technology will improve the half-life of anti-infectives inside target cells, ultimately reducing the repeated dosing that can lead to resistance and toxicity.

The technology - called synthetic ligand for FKBP (SLF) - mimics the interaction between the immunosuppressant tacrolimus (FK506) and FK506 binding protein (macrophilin-12, FKBP)...